At a glance
ClinicalIndex Comparison RecordPhase 3Active· 508 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab for Axial Spondyloarthritis and 3 related conditions. Active but no longer recruiting, targeting 508 participants across 75 sites in 14 countries.
Detailed Summary
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa
CountriesBelgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3Active
202120222023202420252026
Enrollment StartJun 2020
First PostedJun 2020
TodayJul 2026
Primary CompletionAug 2026
First PostedJun 18, 2020
Enrollment StartJun 16, 2020
Primary CompletionAug 7, 2026
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 6.0 years agoPrimary completion in 1 month
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at prespecified time-points.